DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients.

Author(s): Houston JP, Fijal B, Heinloth AN, Adams DH

Affiliation(s): Lilly USA, LLC, Indianapolis, IN 46285, USA. houston_john_p@lilly.com

Publication date & source: 2010-01-30, Psychiatry Res., 175(1-2):171-2. Epub 2009 Nov 5.

Publication type: Clinical Trial; Multicenter Study; Randomized Controlled Trial

In patients from two clinical trials, we investigated the associations of single nucleotide polymorphisms (SNPs) in candidate genes with prolactin level changes during treatment with olanzapine/fluoxetine combination. In both cohorts, three dopamine receptor D2 (DRD2) SNPs were associated with prolactin changes. DRD2 may influence susceptibility to hyperprolactinemia associated with antipsychotic treatment.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017